CD274 and cancer: ICB with antibodies against PD-1 or its ligand (PD-L1) has led to remarkable clinical responses in patients with different types of cancers, including melanomas, non–small-cell lung cancer, renal cell carcinoma, bladder cancer, and Hodgkin’s lymphoma6–12.